Sellas Life Sciences SLS 深 沪
等待开盘 11-02 09:30:00 美东时间
9.68
-0.475
-4.68%
华盛通- 最 高9.79
- 今 开9.63
- 成交量 626.15万股
- 最 低 9.30
- 昨 收 10.155
- 总市值 19.55亿
- 52周最高 15.8765
- 市盈率 静 --
- 换手率 3.10%
- 52周最低 1.39
- 委 比 -99.84%
- 总股本 2.02亿
- 历史最高 554.50
- 量 比 0.70
- 振 幅 4.83%
- 历史最低 0.4986
- 每 手 1
- 风险率 4.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多思路迪医药股份(01244)：3D189全球关键性III期REGAL试验达到预设事件数
思路迪医药股份(01244)发布与SELLAS Life Sciences Group, Inc. (SELLAS)合作项目3D189(Galinpepimu...
10-29 20:31
SELLAS Life Sciences Stock Stumbles: What's Going On?
SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are falling Wednesday, pulling back after trading higher earlier in the day, as the company’s Phase 3 leukemia study moves toward its final analysis. Here’s what you should know. SELLAS Life Sciences Gr stock is feeling bearish pressure. What’s behi...
10-28 22:28
SELLAS Life Sciences Announces Its Pivotal Phase 3 Study Of Galinpepimut-S In Acute Myeloid Leukemia Participants Surpasses Pre-Specified 80th Event
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS’’ or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the pivotal Phase 3 REGAL trial evaluating galinpepimut-S (GPS) in p...
10-28 20:37
SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia
SELLAS Life Sciences Group announced that its pivotal Phase 3 REGAL trial evaluating galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients has reached the pre-specified 80th event, triggering final analysis. The company expects to report topline primary endpoint results this quarter. The REGAL trial aims to assess GPS as a maintenance therapy for AML patients in second complete remission, with overall survival as the primary endpoint. Pos...
10-28 12:35
SELLAS Life Sciences Group Inc.收跌1.73%，成交额3673.36万美元
10月27日，SELLAS Life Sciences Group Inc.（SLS）收跌1.73%，报11.34美元，成交额3673.36万美元，市值22....
10-27 05:23
美股前瞻 | 绩优股盘前飙涨！SpaceX一度升逾10%，AI营收暴增830%；特斯拉、Meta盘后放榜！
绩优股盘前飙涨！SpaceX一度升逾10%，AI营收暴增830%；特斯拉、Meta盘后放榜！木头姐指特斯拉有望涨至5000美元；戴尔预警：明年内存短缺将进一步恶化！>>
10-21 20:21
美股牛股 | BRZE 获收购暴升51.7%；万基遗传涨31.6%，拟2.1亿美元出售产前检测业务；艾可菲升11.3%，净利增32%；孩之宝涨11.2%
BRZE 获收购暴升51.7%；万基遗传涨31.6%，拟2.1亿美元出售产前检测业务；艾可菲升11.3%，净利增32%；孩之宝涨11.2%
10-21 18:13
SELLAS Life Sciences Group Inc.收跌11.99%，成交额1.58亿美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 05:28
SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer
SELLAS Life Sciences Group announced preclinical data showing that its CDK9 inhibitor, SLS009, demonstrated significant anti-tumor activity in MYC-amplified pancreatic ductal adenocarcinoma (PDAC) models, including a daraxonrasib-resistant model. SLS009 induced higher apoptosis and necrosis compared to daraxonrasib alone and further enhanced cancer cell death when combined with daraxonrasib. Additionally, SLS009 combined with the BET inhibitor ZE...
09-25 17:00
When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges
SELLAS Life Sciences Group Inc. (NASDAQ:SLS) stock is trading higher on Thursday. Year-to-date, the stock has surged by around 300%. FDA Approval Catalyst For Pancreatic Cancer SLS’s momentum on Thursday may be related to the U.S. Food and Drug Administration (FDA) on Wednesday approving Revolution ...
08-28 01:13
